Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Reconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based study

Fig. 2

Prognostic impact of the 22-node measure on CCS for patients aged < 40. a 5-year CSSs in all patients between lymph node count ≥22 and < 22; (b) 5-year CSSs in patients with stage I between lymph node count ≥22 and < 22; (c) 5-year CSSs in patients with stage II between lymph node count ≥22 and < 22; (d) 5-year CSSs in patients with stage III between lymph node count ≥22 and < 22

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us